Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)
May 25, 2021 06:26 AM EDT
Deals
Bioregnum

The $70B ques­tion: What’s Pfiz­er go­ing to do with all that Covid vac­cine cash?

Pfiz­er’s lat­est deal a few days ago to sell Eu­rope 1.8 bil­lion dos­es of BioN­Tech’s mR­NA vac­cine — 900 mil­lion guar­an­teed and 900 mil­lion op­tioned …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times